IDVO

The Week

Teva Pharmaceutical Industries (TEVA) closed the week at $39.19, up 0.54%, while the S&P 500 gained 1.21%, leaving the stock about 0.67 percentage points behind the benchmark. The week saw a 6.21% range, with a Monday high of $40.79 followed by a pullback to $39.19 by Friday close, a fade-and-chop pattern overall.

Key Events

The week opened with Phase 3 SOLARIS analyses for a Medincell-backed monthly olanzapine LAI presented at Psych Congress 2026. Teva’s CEO then detailed the biopharma pivot, the $700m savings plan and growth pipeline. Midweek the company secured investment-grade ratings and released its Q3 aide memoire, confirming a 3 November pre-market results call. Director Roberto Mignone also sold 367,600 shares worth around $14.36m.

Analyst Ratings

Among the seven brokers covering Teva this week, three rate it buy, three rate it over and one has no opinion, putting the consensus at buy. The consensus target of $44 sits about 12.3% above the $39.19 close, with a target range of $40 to $50, suggesting limited disagreement. Teva ranks 74th out of 203 names in the pharma industry rating league.

The Week Ahead

Macro data dominates next week, with Dallas Fed manufacturing activity on Monday, then FHFA and Case Shiller home prices, JOLTS job openings and consumer confidence on Tuesday. On the company front, third-quarter 2026 results are due on 3 November before the open, with consensus at $0.4785 EPS and $4.242bn revenue.

In Short

Teva faded from its intraweek highs and lagged the market, but the analyst picture remains favourable, with a buy consensus and a target roughly 12% above spot. The latest session showed large-lot money tilting to the sell side, while valuation reads rich at 64.69x P/E and 5.89x P/B. The next test is whether the early-November quarter can validate the transformation story, against the backdrop of a rate-sensitive tape.

This article is generated by LongbridgeAI from market data, for information only and not investment advice.